ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Hideo Tomihara
Matched on ORCID iD 0000-0003-4392-1187; OpenAlex author ID A5066425406. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 29
2017: 3 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper
Papers 6
- PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-021-24798-y↗
- A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-19-4044↗
- Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/0008-5472.can-19-0187↗
- Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-016-1405-6↗
- The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Co-author DOI 10.1007/s00595-017-1522-x↗
- MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Co-author DOI 10.1111/cas.13159↗
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masahiro Tanemura · 3 shared papers, 2017 · strength 0.19
- Paper Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreati… DOI 10.1007/s00595-016-1405-6↗
- Paper The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. DOI 10.1007/s00595-017-1522-x↗
- Paper MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiat… DOI 10.1111/cas.13159↗
- Tadafumi Asaoka · 3 shared papers, 2017 · strength 0.19
- Paper Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreati… DOI 10.1007/s00595-016-1405-6↗
- Paper The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. DOI 10.1007/s00595-017-1522-x↗
- Paper MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiat… DOI 10.1111/cas.13159↗
- Yuichiro Doki · 3 shared papers, 2017 · strength 0.19
- Paper Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreati… DOI 10.1007/s00595-016-1405-6↗
- Paper The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. DOI 10.1007/s00595-017-1522-x↗
- Paper MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiat… DOI 10.1111/cas.13159↗
- Hidetoshi Eguchi · 3 shared papers, 2017 · strength 0.19
- Paper Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreati… DOI 10.1007/s00595-016-1405-6↗
- Paper The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. DOI 10.1007/s00595-017-1522-x↗
- Paper MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiat… DOI 10.1111/cas.13159↗
- Daisaku Yamada · 3 shared papers, 2017 · strength 0.19
- Paper Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreati… DOI 10.1007/s00595-016-1405-6↗
- Paper The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. DOI 10.1007/s00595-017-1522-x↗
- Paper MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiat… DOI 10.1111/cas.13159↗
- Kunihito Gotoh · 3 shared papers, 2017 · strength 0.19
- Paper Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreati… DOI 10.1007/s00595-016-1405-6↗
- Paper The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. DOI 10.1007/s00595-017-1522-x↗
- Paper MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiat… DOI 10.1111/cas.13159↗
- Yutaka Takeda · 3 shared papers, 2017 · strength 0.19
- Paper Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreati… DOI 10.1007/s00595-016-1405-6↗
- Paper The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. DOI 10.1007/s00595-017-1522-x↗
- Paper MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiat… DOI 10.1111/cas.13159↗
- Alessandro Carugo · 2 shared papers, 2019–2021 · strength 0.15
- Paper PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-021-24798-y↗
- Paper Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocar… DOI 10.1158/0008-5472.can-19-0187↗
- Jason B. Fleming · 2 shared papers, 2019–2021 · strength 0.15
- Paper PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-021-24798-y↗
- Paper Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocar… DOI 10.1158/0008-5472.can-19-0187↗
- Michael P. Kim · 2 shared papers, 2019–2021 · strength 0.15
- Paper PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-021-24798-y↗
- Paper Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocar… DOI 10.1158/0008-5472.can-19-0187↗
- Giulio Francesco Draetta · 2 shared papers, 2019–2021 · strength 0.15
- Paper PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-021-24798-y↗
- Paper Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocar… DOI 10.1158/0008-5472.can-19-0187↗
- Raju Kandimalla · 1 shared paper, 2020 · strength 0.13
- Hideo Baba · 1 shared paper, 2020 · strength 0.13
- Kensuke Yamamura · 1 shared paper, 2020 · strength 0.13
- Ajay Goel · 1 shared paper, 2020 · strength 0.13
- Masaki Mori · 2 shared papers, 2017 · strength 0.13
- Paper Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreati… DOI 10.1007/s00595-016-1405-6↗
- Paper The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. DOI 10.1007/s00595-017-1522-x↗
- Andrea Viale · 1 shared paper, 2021 · strength 0.08
- Virginia Giuliani · 1 shared paper, 2021 · strength 0.08
- Timothy Paul Heffernan · 1 shared paper, 2021 · strength 0.08
- Giannicola Genovese · 1 shared paper, 2021 · strength 0.08
- Johnathon Lynn Rose · 1 shared paper, 2021 · strength 0.08
- Haoqiang Ying · 1 shared paper, 2021 · strength 0.08
- Anirban Maitra · 1 shared paper, 2021 · strength 0.08
- Timothy Anthony Yap · 1 shared paper, 2021 · strength 0.08
- Carla Mottini · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.